NCT04709913View on ClinicalTrials.gov

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

April 30, 2021

Study Completion Date

July 30, 2021

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

HU6

HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Trial Locations (1)

55114

Prism Clinical Research, Minneapolis

All Listed Sponsors
lead

Rivus Pharmaceuticals, Inc.

INDUSTRY

NCT04709913 - Multiple Ascending Dose Study of HU6 in High BMI Volunteers | Biotech Hunter | Biotech Hunter